ARRIS - Another partner Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARRIS - Another partner

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (325)	12/24/1997 1:25:00 AM
From: Miljenko Zuanic	Read Replies (1) of 353

John: >>Miljenko, in which respect do you think ARRS/MRK are wasting money?<< I am only asking for opinion. By PNAS article (which has surprise me) it appears that SKB have significant time advantage over ARRS/Merck on osteoporosis. It is a very serious article. In my last conversation with ARRS IR, they told me that it will take min. two-three years before any candidate enter pre-clinical study. Probably SKB has several patents application on this class molecules at this time and it may cover potential inhibitors very well. I am not speculating, but it is possibility that ARRS work will be blocked. You are right about firewall and it is unpleasant situation for ARRS personnel. I hope that they are not surprised as I am. mz PS: If you attend H&Q conference this issue may be very interesting question.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next